First patients in UMC Utrecht treated with new technique for heart rhythm disorders
UMC Utrecht, along with three other centers in Europe, successfully treated the first patients with severe cardiac arrhythmias worldwide with Abbott’s new ablation system. This new technique uses extremely short electrical pulses instead of heating or freezing heart tissue. For patients with atrial fibrillation, this technique is safer, more effective and faster. This promising treatment is now expected to be used increasingly in Europe for patients with cardiac arrhythmias.
Atrial fibrillation is the most common cardiac arrhythmia worldwide. In patients with atrial fibrillation, the electrical excitation and conduction in the atria of the heart is disturbed. At UMC Utrecht, together with Abbott, a new ablation system (VoltTM PFA) has been developed with which atrial fibrillation can be surgically treated. This technique consists of a newly developed balloon catheter and uses short electrical pulses (Pulsed Field Ablation). With this, the cardiologist switches off the part of the heart that is causing the arrhythmia. This is done through a tube inserted into the heart through a blood vessel.
Promising new treatment technique
UMC Utrecht is one of the first hospitals in Europe to use the new treatment technique. In total, the first sixteen patients with atrial fibrillation in four centers in the Netherlands, Austria, Germany and Belgium have now been treated with this technique. “It is one of the most startling techniques in electrophysiology, a real game changer,” said Peter Loh, cardiologist-electrophysiologist at UMC Utrecht. “The expectation is that this promising treatment will now be increasingly used in Europe for patients with atrial fibrillation.”
Treatment safer, more effective and faster
Scientific studies show that the treatment is safe and effective for patients with atrial fibrillation. Peter Loh: “Because the electric pulse is ultra-short, essentially no heat is created and, as a result, patients experience few side effects. The treatment is safe and could take place within an hour. This is faster than standard ablation treatment by heating heart tissue, which usually takes two to three hours. The shorter surgery time will likely allow us to offer treatment to more patients.”
Probability of arrhythmia recurrence expected to be reduced
The new treatment technique allows cardiologists to treat the right spots in the heart precisely and effectively. Peter Loh: “We also expect long-term results to improve with the new VoltTM PFA ablation system. After treatment with the existing techniques, about thirty percent of patients develop atrial fibrillation again and often have to undergo a second ablation. With the new system that uses a balloon catheter, the chance of the arrhythmia returning is expected to be reduced, future research will show.”
Eight million Europeans
An estimated eight million Europeans over the age of 65 are currently living with atrial fibrillation. This number is expected to double within 30 years. In the Netherlands, more than 400,000 people have atrial fibrillation. In addition, there are an estimated 80,000 people with atrial fibrillation who do not know because they have never been diagnosed. Atrial fibrillation increases the risk of stroke, heart failure and death.
Works on the tram track at Padualaan in Utrecht Science Park
To make public transport future-proof, Strukton is carrying out works on the tram track on Padualaan in Utrecht Science Park on behalf of the Province of Utrecht. In mid-January, works on the track will start near Weg tot de Wetenschap, just beyond the tram stop.
High-tech robots and laser scanners: this laboratory is where the food of the future is being discovered.
A remarkable world of high-tech robots, laser scanners, climate chambers, and other advanced equipment is hidden inside an inconspicuous, windowless building at Utrecht Science Park—a world entirely focused on the question of how to feed the global population in 2050.
Together in action for 3FM Serious Request and Spieren voor Spieren
During 3FM Serious Request the whole of the Netherlands came into action for Spieren voor Spieren. A lot of money was raised that can really make a difference for children with a muscular disease: the final amount is € 18,423,566. With the money, Spieren voor Spieren can do research on treatment and medication, faster diagnosis and exercise for children with a muscular disease.
Wennink plan: Life Sciences and biotechnology are important growth drivers for the earning capacity of the Netherlands
The Dutch Life Sciences and biotechnology sector can make a much larger contribution to the Netherlands’ economic strength. This is shown in a new growth strategy presented today as part of Peter Wennink’s advisory report. The report also highlights Utrecht Science Park as one of the key innovation locations and sources of progress and growth.